

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of: **Michael Birsha DAVIES, et al.**

Serial No.: **To be assigned**

Art Unit: **To be assigned**

Filing Date: **Concurrently Herewith**

Examiner: **To be assigned**

For: **A FLUID DISPENSING DEVICE**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the following references are enclosed. References # 21-47
☐ Copies of the references were submitted in parent application Serial No. _____. (37 CFR 1.98(d))
☒ A copy of the International Search Report which issued on International Application No. PCT/GB2004/004626 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- OR
- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
- (1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.
- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☒ A duplicate copy of this paper is attached.

Respectfully Submitted,



Alice P. Bradney
Agent for Applicants
Registration No. 51,491

Date: May 3, 2006
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483- 9024
Facsimile: (919) 483-5730

10/577977

10/23/2006 10:10:10 US MAY 2006

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.

[X] A duplicate copy of this paper is attached.

Respectfully Submitted,



Alice P. Bradney
Agent for Applicants
Registration No. 51,491

Date: May 3, 2006
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483- 9024
Facsimile: (919) 483-5730

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

111 207 977

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO. PB60512	SERIAL NO. To Be Assigned
	APPLICANT: Michael Birsha DAVIES, et al.	
	FILING DATE: Concurrently Herewith	GROUP To Be Assigned

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1.	3,272,391	09/13/1966	MESHBURG			
	2.	4,083,476	04/11/1978	SCHWARTZ, et al.			
	3.	4,771,769	09/20/1988	HEGEMANN, et al.			
	4.	4,860,738	08/29/1989	HEGEMANN, et al.			
	5.	4,921,142	05/01/1990	GRAF, et al.			
	6.	4,944,429	07/31/1990	BISHOP, et al.			
	7.	4,946,069	08/07/1990	FUCHS			
	8.	5,062,549	11/05/1991	SMITH, et al.			
	9.	5,487,489	01/30/1996	WEISS, et al.			
	10.	5,899,365	05/04/1999	EICHLER, et al.			
	11.	6,189,739	02/20/2001	VON SCHUCKMANN			
	12.	6,305,371	10/23/2001	FRID, et al.			

Continue on page 2

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	21.	173 123	12/29/1921	GB			
	22.	659 132	10/17/1951	GB			
	23.	1 097 254	01/03/1968	GB			
	24.	1 481 199	07/27/1977	GB			
	25.	2 570 000	03/14/1986	FR			√ Abstract
	26.	0 412 524	02/13/1991	EP			
	27.	2 671 294	07/10/1992	FR			
	28.	2 251 898	07/22/1992	GB			
	29.	09048455	02/18/1997	JP			√ Abstract
	30.	09225363	09/02/1997	JP			√ Abstract
	31.	196 10 456	09/18/1997	DE			√ Abstract
	32.	09313998	12/09/1997	JP			√ Abstract

Continue on page 2

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

Continue on page

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.